Sporotrichosis medical therapy: Difference between revisions
Jump to navigation
Jump to search
| Line 12: | Line 12: | ||
|- | |- | ||
|Uncomplicated cutaneous | |Uncomplicated cutaneous | ||
| | |Itraconazole [200 mg/day] | ||
| | |Itraconazole [200 b.i.d.], | ||
| | |||
terbinafine [500 b.i.d.], | |||
SSKI [increasing doses], | |||
fluconazole [400-800 mg/day], or | |||
local hyperthermia | |||
|Continue treatment for 2-4 weeks | |||
after lesions resolve. | |||
|- | |- | ||
|Osteoarticular | |Osteoarticular | ||
| | |Itraconazole [200 mg b.i.d.] | ||
| | | | ||
| | | | ||
Revision as of 15:17, 12 January 2016
|
Sporotrichosis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Sporotrichosis medical therapy On the Web |
|
American Roentgen Ray Society Images of Sporotrichosis medical therapy |
|
Risk calculators and risk factors for Sporotrichosis medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Treatment
| Form | Primary Line of Treatment | Alternative Treatment | Remarks/Other |
|---|---|---|---|
| Uncomplicated cutaneous | Itraconazole [200 mg/day] | Itraconazole [200 b.i.d.],
terbinafine [500 b.i.d.], SSKI [increasing doses], fluconazole [400-800 mg/day], or local hyperthermia |
Continue treatment for 2-4 weeks
after lesions resolve. |
| Osteoarticular | Itraconazole [200 mg b.i.d.] | ||
| Pulmonary | |||
| Meningeal | |||
| Dissimated | |||
| Sporotrichosis in pregnant women | |||
| Sporotrichosis in Children |